Formulary guidance and transparency from P&T to point of care


Reality Check on Sickle Cell Disease

Market access for sickle cell disease treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.  

To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:

  • Payer Insights: Under the pharmacy benefit, about 22% of the lives under commercial formularies are covered with utilization management restrictions
  • Class Trends: In November 2019, the FDA gave accelerated approval to Global Blood Therapeutics, Inc.'s Oxbryta (voxelotor) for the treatment of sickle cell disease in people at least 12 years old. The company says it's the first FDA-approved treatment that targets the root cause of the disease
  • Key Findings: Endari and Siklos have very little unrestricted access versus Droxia in this indication. Adakveo requires prior authorization and is covered under both the pharmacy and medical benefit, while Oxbryta falls under the pharmacy benefit

What can pharma do to curb this trend and overcome these challenges?

Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.

Download the full Reality Check now.